

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 35/74, C12N 1/20	A1	(11) International Publication Number: WO 93/01823 (43) International Publication Date: 4 February 1993 (04.02.93)
(21) International Application Number: PCT/SE92/00528 (22) International Filing Date: 24 July 1992 (24.07.92) (30) Priority data: 9102238 25 July 1991 (25.07.91) SE (71) Applicant (for all designated States except US): PROBI AB [SE/SE]; Forskningsbyn Ideon, S-223 70 Lund (SE). (72) Inventors; and (75) Inventors/Applicants (for US only) : MOLIN, Göran [SE/SE]; Examensvägen 2, S-223 67 Lund (SE). AHRNE, Siv [SE/SE]; Domarevägen 19, S-237 00 Bjärred (SE). BENGMARK, Stig [SE/SE]; Box 5003, S-222 05 Lund (SE). JEPPSON, Bengt [SE/SE]; Mätaregränden 8, S-222 47 Lund (SE).		(74) Agents: LARFELDT, Helene et al.; Bergensträhle & Lindvall AB, Box 17704, S-118 93 Stockholm (SE). (81) Designated States: AU, CA, FI, JP, NO, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE). Published <i>With international search report.</i>
(54) Title: INTESTINE COLONIZING LACTOBACILLI (57) Abstract A process for isolation of a strain of Lactobacillus having the ability of being established on human intestinal mucosa in vivo and being able to remain therein after oral administration for at least 10 days after the completion of the administration. By the process the new strains L. plantarum 299 (DSM 6595) and L. casei ssp. rhamnosus 271 (DSM 6594) have been isolated, which are useful for the prophylaxis or treatment of bacterial infections, especially in the form of a fermented nutrient composition.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MI	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

Intestine colonizing lactobacilli

The present invention refers to a process for isolation
5 of strains of Lactobacillus having the ability to colonize
and become established on intestinal mucosa in vivo after
oral administration, strains obtained by this process, and
the use thereof for the prophylaxis or treatment of bacterial
infections, especially in the form of a composition com-
10 prising an oatmeal based nutrient solution fermented by one
of said strains.

Many people have a disturbed intestinal microflora, that
is, the balance between useful and harmful intestinal bac-
teria is disturbed. A number of factors, among others stress,
15 the occurrence of bile salts, diet, etc. influence the bac-
terial flora. Most important is, however, that modern anti-
biotic treatment can destroy the normal flora for a long
period of time, and thus, eliminate a normal fermentation
process. Should the fermentation process be disturbed and the
20 number of useful bacteria be reduced, the consequence will be
that the colon mucosa withers away and ceases to function at
the same time as the potentially malignant bacteria rapidly
grow in number. These bacteria penetrate the malfunctioning
colon wall and infect the organs of the body which leads to
25 the so called intensive-care-disease with pus foci all over
the body and possibly also an abolished function of most of
the organs of the body, a collapse of organs. Blood poison-
ing, sepsis, caused by abscesses in the abdominal cavity is
still a very common surgical complication in connection with
30 abdominal surgery with a high death-rate. These patients are
today treated by administration of antibiotics and surgical
treatment of the abscess to the extent it could be located.
At present antibiotics are conventionally administered before
intestinal surgery in order to reduce the risk of post-
35 operative infections and illness caused thereby. However, the
treatment with antibiotics is expensive and moreover as-
sociated with a risk of different complications such as
allergy and destruction of the normal intestinal flora and
overgrowth with still more pathogenic bacteria.

The fact that lactobacilli should have a favourable effect on the intestinal mucosa is an old idea which has been brought up again. There are however many unclear points as to which microorganisms are involved and as to the ecology of the intestines. Another problem in this connection is that the classification of the genus *Lactobacillus* is incomplete which makes it difficult to identify those strains which are favourable to the function of the intestines. What, after all, seems to be commonly accepted today is that:

10

- Bacteria of the genus *Lactobacillus* have a manifest ability of preventing the establishing of pathogenic bacteria in various ways, irrespective of foodstuffs or intestines being concerned;
- 15 - Certain strains of *Lactobacillus* are more effective than other strains of the same species in protecting and activating the intestines;
- Foodstuffs fermented by lactobacilli have proven to have a cholesterol reducing effect, probably because of a checking of the cholesterol production in the
20 intestines, but maybe also because the bacteria use cholesterol for the production of steroids;
- The consumption of great amounts of lactobacilli improves the intestinal motoric activity, the cause
25 of this effect is unknown;
- A large proportion of lactobacilli in the intestines counteracts cancer, something which seems to have several grounds. Firstly, certain lactobacilli are able to prevent the production of nitroamines in
30 the intestines by means of the enzyme nitroreductase; nitroamines are cancerogenic. Secondly, lactobacilli may obstruct certain bacterially produced enzymes in the intestines from activating potentially carcinogenic substances. Finally, there
35 are indications of lactobacilli having growth restricting effect on cancer tumours, maybe because the macrophages of the immunological defence system are activated by the presence of the lactobacilli.

A decisive weakness of the lactobacilli used today in most conventional foodstuffs is the poor survival of these organisms during the passage through the stomach and duodenum. This brought about the development of a product
5 called "acidophilusfil", acidophilus sourmilk, wherein milk was fermented with a strain of *Lactobacillus acidophilus* isolated directly from human faeces. *L. acidophilus* manages the passage through the upper part of the gastro-intestinal tract well. However, in order to have an effect on the micro-
10 flora in the intestines for a longer period of time, it is essential that the lactobacillus is able to become established in the intestines. According to Lidbeck, A et al, Scand J Infect Dis, 4, pp 531-537, 1987, the increase in the number of lactobacilli in the microflora of the intestines,
15 which occurs after consumption of a preparation containing *Lactobacillus acidophilus*, is gradually slowing down as the consumption thereof ceases, and consequently after 9 days without supply the bacterial flora has regained its original composition.

20 EP-A2-0 199 535 describes a biologically pure culture of *Lactobacillus acidophilus*, ATCC accession No. 53 103, isolated from human faeces, being able to adhere to mucosal cells in tests in vitro. An adherence in vivo has, however, not been demonstrated.

25 WO 89/05849 describes lactic acid bacteria isolated from the gastro-intestinal tract in pigs and selected by means of, among others, adhesion to gastro-intestinal epithelial cells from pigs in vitro and tolerance against acid and bile. Said bacteria can be used for the fermentation of milk which then
30 can be given to piglets to prevent or treat i.a. *E. coli* diarrhoea.

The strains of *Lactobacillus* which are commercially used today have above all been selected for being passably capable of growing in current primary products as for example milk.
35 If a certain strain is to exercise an optional favourable influence, it is without doubt a prerequisite that it is able to become established in the intestines and to compete with the existing microflora. Knowledge about which properties are necessary for a certain *Lactobacillus* strain to be able to

stand this competition is for the most part unknown.

The present invention refers to a process for isolation of a strain of *Lactobacillus* having the ability to colonize and become established on human intestinal mucosa in vivo, characterized in that lactobacilli are isolated from human intestinal mucosa and are pure cultured in a suitable nutritient medium and then selected as to the ability to colonize and become established in the intestines.

The ability of the strain to colonize in the intestines is preferably tested by oral administration, and a subsequent verification of the occurrence on the intestinal mucosa at least 10 days after the completion of the administration.

A complementary selection of isolated strains can take place, before or after the test of the colonization, by an evaluation of different functional and technical properties, such as bile resistance, pH-resistance, ability of fermentation of a requested substrate, preferably oatmeal, and of producing flavour, ability to resist freeze-drying, antibiotics resistance, etc.

To manage the passage through the gastro-intestinal tract the selected strains thus ought to be able to survive at a pH of 1.0 for 30 minutes and also to grow in the presence of 0.1% bile.

The invention also refers to strains of *Lactobacillus* having the ability of colonizing human intestinal mucosa in vivo, obtained by the isolation process described above. According to one theory the strains of *Lactobacillus* which are facultatively heterofermentative constitute a preferred type for the establishment in the intestines.

The invention especially refers to new *Lactobacillus* strains having the ability of colonizing human intestinal mucosa in vivo, which have been deposited according to the Budapest Agreement at the DSM - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH -, Braunschweig, Germany on July 2, 1991, that is

Lactobacillus plantarum 299

DSM 6595

Lactobacillus casei ssp. *rhamnosus* 271

DSM 6594

The invention also refers to variants thereof having an essentially corresponding REA-pattern. A REA-pattern refers to the pattern formed in electrophoresis on agar gel of DNA which has been decomposed with a restriction enzyme according to the method described below. By characterization of the strains by means of their REA-pattern the identity of the used isolates can be established, something which has not been possible before. Closely related strains of *Lactobacillus* with differences in the REA-pattern show differences as to the ability of adherence to intestinal epithelium.

The invention also refers to a composition for the prophylaxis or treatment of infections in the gastro-intestinal tract, which comprises a *Lactobacillus* strain having the ability to colonize and become established in human intestinal mucosa in vivo, which has been obtained according to the method of the invention, combined with a conventional carrier.

In particular the invention refers to a composition comprising any of the strains

<i>Lactobacillus plantarum</i> 299	DSM 6595
<i>Lactobacillus casei</i> ssp. <i>rhamnosus</i> 271	DSM 6594

or a variant thereof having an essentially corresponding REA-pattern.

Conventional carriers are for example physiologically acceptable substrates fermented by the bacterium in question, as well as foodstuffs of various kinds, especially based on starch or milk, but also inert solid or liquid substances, such as saline or water. A suitable substrate should contain liquid or solid fibres which are not resorbed in the gastro-intestinal tract and which when fermented with *Lactobacillus* form short fatty acids. As an example of suitable, starch-containing substrates can be mentioned cereals, such as oats and wheat, corn, root vegetables such as potatoes and certain fruits such as green bananas.

Modern medical care of patients in connection with illness and surgery is to a large extent based on the supply of nutrition via the veins, whereby the intestines are not

supplied with material to ferment with subsequent consequences. The colon functions as the body's own fermentation tank, the purpose of which is to produce useful nutrients, among others for the function of the colon itself, but also for
5 eliminating harmful substances, for example heavy metals, excessive amounts of cholesterol etc. In order for the colon to function there must be a supply of suitable bacteria and substrates, particularly starch and dietary fibres. About
10 half of the contents of the colon is bacteria, mostly of the anaerobic type. The most important bacteria are those located on the colon mucosa. Among the bacteria of the colon there is a minority of a potentially harmful type. As long as the useful bacteria are present the harmful bacterial flora is suppressed. Recent studies have shown that the colon mucosa
15 obtains most of its nutrition from fermentation products, mainly in the form of short fatty acids. A normal fermentation process requires a supply of about 30 g of dietary fibre daily and the presence of suitable bacteria.

A preferred substrate for the composition according to
20 the invention, which also gives the composition an excellent nutritional value, is a nutrient solution based on oatmeal. The cereal oats has shown to be a good substrate for fermentation in many ways: It is rich in proteins, carbohydrates, fat, dietary fibre and also water-soluble fibre, so called
25 β -glucans. In addition oats or oatmeal fat has a very high content of surface-active phospholipids, which function as gastric mucosal barrier "corrosion inhibitors" and hence give mucosal protection. Finally, the amino acid composition of oat proteins corresponds to a large extent to the needs of
30 the human body. In WO 89/08405 a nutrient composition is described suitable for enteral feeding, which is obtained by a combination of enzymatic decomposition of oatmeal with α -amylase, possibly protease, and β -glucanase and heat treatment and fermentation with a lactobacillus having the ability
35 to adhere to the intestines spontaneously. The nutrient composition described in the referred patent application is in combination with a Lactobacillus strain according to the invention an excellent composition for nutrient administration to patients in connection with the normal treatment

after large operations, for special treatment of patients being victims of the intensive-care-disease or an organ collapse, and for treatment of different intestinal diseases, for example ulcerative colitis.

5 To be useful in an oatmeal based nutrient composition according to the invention a Lactobacillus strain should fulfil the following conditions:

- good fermentation of oats;
- survival at a pH of 1.0 (which corresponds to the pH
10 in the stomach) for 30 minutes;
- survival and growth in the presence of bile salts;
- ability of settling and remaining on the intestinal mucosa.

It is also essential that the pH-value during the fermentation is reduced quickly in order to stop the growth of
15 other bacteria.

It has been shown that the administration of lactobacilli having the ability to colonize in or adhere to the intestines can suppress a different bacterial flora from colonizing the
20 intestines and thus reduce the risk of sepsis in connection with bacterial infections such as complications following abdominal surgery. This treatment seems to be as efficient as the conventional treatment used today in the form of antibiotics. Hence, it seems to be reasonable that patients
25 who are subjected to intestinal surgery are pretreated with lactobacilli rather than antibiotics. This means that a cheaper form of therapy could be established with less potential secondary effects as the normal intestinal flora would not be destroyed.

30 The invention also refers to the use of a nutrient composition fermented by a Lactobacillus strain in accordance with the invention instead of antibiotics for the prophylaxis or treatment of bacterial infections in connection with surgical operations, post surgical rehabilitation etc.

35 It especially refers to an oatmeal based nutrient solution fermented by Lactobacillus plantarum 299.

Experiments with test animals have shown a statistically valid survival in animals treated with a composition comprising a Lactobacillus strain isolated from the intestinal mu-

cosa of an animal of the same species. Tests with rats have shown a good prevention and quicker healing of experimentally induced colitis (colit) and ulcers in the intestines.

The composition according to the invention can be administered in any suitable way, preferably orally or rectally, for example in the form of enema. It can also be administered enterally through a catheter inserted in the intestines via the stomach or directly in the intestines. Tests have shown that the effect is improved if dietary fibres in the form of for example oatmeal gruel or of β -glucans are supplied. The treatment should take place once or several times daily for a period of 1 - 2 weeks.

On the enclosed drawings Figures 1 - 2 show the REA-pattern of the new Lactobacillus strains 299 and 271; and Figure 3 shows the concentration of lactobacilli in ileum before, immediately after, and a few days after, respectively, oral administration of an oatmeal gruel fermented by Lactobacillus.

20 **EXAMPLES**

Isolation of Lactobacillus strains from humans

In order to isolate strains having the ability to colonize and become established on human intestinal mucosa, strains of Lactobacillus have been sampled from human mucosa. Biopsies from colon were taken by means of enteroscopy and pieces of the intestinal mucosa from the small intestine (jejunum and ileum) were removed in connection with surgical operations. The mucosa samples were immediately placed in a special medium (0.9% NaCl, 0.1% pepton, 0.1% Tween 80 and 0.02% cystine; all values refer to % by weight/volume), homogenized in ultrasonic baths for 2 minutes and stirred for 1 minute before being placed on Rogosa agar (Difco Laboratories, Detroit, Michigan, USA). The plates were incubated anaerobically at 37°C for 2 d (Gas Pak Anaerobic System, BBL). One to three colonies were picked at random from each plate and were grown in pure cultures 5 to 9 times on Rogosa agar and kept as dense cultures in a frozen buffer at -80°C. A total of 209 Lactobacillus strains were isolated from about 61 different subjects. All isolates were characterized as to

the ability of fermenting 49 different carbohydrates by means of API 50 CH, a commercial test kit from API, Montalieu Vercieu, France. No significant difference in the composition of the lactobacilli flora between the small and the large
5 intestines could be found.

Representative strains from the different groups were evaluated as to pH-resistance, ability of growing in the presence of bile, and ability of fermenting oatmeal gruel.

The pH-resistance was tested by adding 0.1 ml bacterial
10 suspension (10^9 CFU/ml which had been cultivated in Rogosa broth, centrifuged and resuspended in a physiological salt solution) to 2 ml phosphate buffer at pH 1.0. After 30 minutes Rogosa agar plates were inoculated and if any growth was visible after incubation at 37°C for 3 days the test was
15 considered to be positive. Only a few of the tested strains passed this test.

Growth in the presence of bile was tested by growing isolates of Lactobacillus in the presence of 0.1% and 0.15%, respectively, beef bile in Rogosa agar plates incubated
20 anaerobically for 3 days at 37°C. About 80% of the strains were able to grow in the presence of 0.1% bile, whereas only 18% managed to grow in 0.15% bile.

Based on the results of these tests 20 different Lactobacillus strains were selected for further investigation.

25

Intestinal colonization in vivo in humans

Healthy test subjects were for a certain period of time daily given a fermented oatmeal gruel comprising a mixture of twenty different strains of Lactobacillus, carefully selected
30 in accordance with the above. It was then investigated which of the consumed strains could be found on the mucosa from the small and large intestine.

Fermented oatmeal gruel was made according to the protocol described below. This was done with each of the strains
35 of Lactobacillus in the study, as stated in Table 1 below. The different preparations were mixed in such proportions that the final product contained 8×10^7 CFU per gram freeze-dried product.

In the study 12 volunteers aged between 31 and 56 years

participated, each of which received ten bottles of 100 ml liquid oatmeal gruel based on 1 g freeze-dried product per ml water. Samples from the intestinal mucosa were taken before the consumption of the oatmeal gruel had started, after 11 days when the subjects had consumed 100 ml oatmeal gruel for breakfast daily for a period of 10 days, and after another 10 days, that is 11 days after the completion of the oatmeal gruel consumption. The intestinal samples were taken as biopsies from the small intestine (ileum) by means of a Watson capsule, and from rectum with a rectoscope. The biopsies were prepared as described above and analysed as to the contents of viable *Lactobacillus*. From each sample about ten colonies were picked from the Rogosa agar plate, which were grown in pure cultures and freeze-stored at -80°C until they were identified.

All isolates were tested on API 50 CH as above. The isolates that seemed to correspond with or mainly correspond with any of the test strains were tested further by plasmid analysis and restriction endonuclease analysis according to the methods described below.

As a general trend it was observed that the content of lactobacilli on the intestinal mucosa was increased during the consumption of fermented oatmeal gruel and that this increase was continued for 11 days after the completion of the administration. In Figure 3 the logarithmic concentration of lactobacilli in ileum is shown by means of a column diagram before the start of the test ($t=0$), on the day after the completion of the test ($t=1$) and after another 10 days ($t = 11$). The increase was more pronounced in the small intestine, but on the other hand the content of lactobacilli as a whole was larger in the large intestine. Furthermore, it could be noted that the contents of Gram negative anaerobic bacteria in the colon were reduced after the consumption of the fermented oatmeal gruel.

The following strains were found in a dominating position on the intestinal mucosa 10 days after the completion of the administration of lactobacilli:

Lactobacillus plantarum 299 was found in 11 subjects (in 5 subjects only on the small intestine and in 5 others only

on the large intestine);

Lactobacillus casei ssp. *rhamnosus* 271 was found in 4 subjects (in 1 only on the small intestine and in 2 others only on the large intestine);

- 5 *Lactobacillus reuteri* 108 was found in 4 subjects (in 1 only on the small intestine and in 1 other only on the large intestine);

Lactobacillus murinus/casei ssp. *tolerance* 294 was found in 2 subjects.

- 10 The strains which were reisolated 11 days after the completed administration were found on the mucosa in an approximate concentration of 3×10^3 to 10^5 CFU/g mucosa for the small intestine and a concentration of 10^3 to 3×10^7 CFU/g mucosa for the large intestine.

15

Preparation of oatmeal gruel

Fermented oatmeal gruel was made in three steps:

- (i) 1295 g oatmeal (MP-450, Nord-Mills, Järna; protein content 14.2% and ash content 2.1%), 129.5 g
20 enzyme mixture (Nord Malt, Söderhamn) and 5390 g tap water were mixed and heated to 95°C during slow stirring. The gruel was cooled to 50°C, 1% β -glucanase (weight/volume) was added (GV-L; Grindsted Products A/S, Braband, Denmark) and
25 then was incubated for 2 hours at 50°C;
- (ii) The gruel was inoculated with fresh lactobacilli and fermented at 37°C for 15-20 hours. The pH was 3.4 to 3.9. The fermentation was carried out with the different strains each separately and the
30 number of colony forming units, CFU, per ml product varied between 6×10^6 and 2×10^8 on Rogosa agar (anaerobically at 37°C for 20 hours);
- (iii) The fermented gruel was freeze-dried. The different products were mixed in such a proportion
35 that the same value of CFU/g was obtained for all the strains. The mixture was supplemented with 20% (w/w) soybean flour (protein 51%, ash content 5.5%, fat 1%). The enriched mixture contained 2×10^7 CFU/g and was kept at -18°C. Non-fermented

oatmeal gruel was made in the same way as above,
but without fermentation.

Oatmeal gruel was made with all the 20 strains which had
been selected for the intestine colonization test described
5 above and was evaluated as to the concentration before and
after freeze-drying and as to flavour. The results are given
in Table 1 below.

Table 1Selected strains of *Lactobacillus* for clinical tests

5	Strain No.	Description	CFU/g	CFU*/g	Flavour***
	138	"aggregating"	8,8 x 10 ⁸	1,78 x 10 ⁸	1
	132	<i>L. salivarius</i>	1,1 x 10 ⁸	6,5 x 10 ⁶	3
10	47	<i>L. reuteri</i>	1,2 x 10 ⁹	3,7 x 10 ⁷	1
	108	<i>L. reuteri</i>	1,5 x 10 ⁹	1,88 x 10 ⁷	1
	98	<i>L. casei</i> pseudo-plantarum	1,63 x 10 ⁹	6,6 x 10 ⁸	2
	292	<i>L. gasseri</i>	1,58 x 10 ⁹	5,1 x 10 ⁸	4
15	299	<i>L. plantarum</i>	1,92 x 10 ⁹	6,71 x 10 ⁸	5
	136	<i>L. casei casei</i>	3,5 x 10 ⁹	1,48 x 10 ⁹	2
	A1	<i>L. plantarum</i>	2,27 x 10 ⁹	4,15 x 10 ⁸	5
	271	<i>L. casei</i> rhamnosus	4,3 x 10 ⁹	6,10 x 10 ⁸	4
20	227	<i>L. buchneri</i>	9,45 x 10	1,81 x 10 ⁸	1
	140	<i>L. gasseri</i>	1,2 x 10 ⁸	8,5 x 10 ⁶	4
	294	<i>L. murinus/casei</i> tolerance	1,63 x 10 ⁹	1,3 x 10 ⁸	3
	283	<i>L. plantarum</i>	7,43 x 10 ⁸	7,55 x 10 ⁷	4
25	282	cluster 25**	7,8 x 10 ⁸	6,65 x 10 ⁷	2
	96	cluster 19**	4,9 x 10 ⁸	4,3 x 10 ⁷	3
	99	cluster 12**	4,6 x 10 ⁹	1,39 x 10 ⁹	4
	99*	cluster 12**	1,0 x 10 ⁹	1,6 x 10 ⁸	2
	308	<i>L. acidophilus</i>	5,9 x 10 ⁸	1,0 x 10 ⁸	3
30	280	<i>L. salivarius</i>	3,0 x 10 ⁸	2,43 x 10 ⁶	3

* after freeze-drying

** the cluster-numbering refers to a work in numerical taxonomy on intestine associated lactobacilli by Molin G et al

35 (under publication).

*** on a scale 5-1

The ability of giving the oatmeal gruel a pleasant flavour by the fermentation was judged by an "expert panel" consisting of four persons who judged the oatmeal gruels

40

fermented by different strains. The flavour was estimated in a dropping scale from 5 to 1, where 5 denotes the judgement "very good" and 1 the judgement "unsavoury". The values for the 20 selected test strains are shown in Table 1 above.

5

Fermentation of oatmeal gruel

The four strains which were found on the intestinal mucosa in a dominating amount were investigated further as to the ability to ferment oatmeal gruel, the ability to resist freeze-drying and as to the development of flavour in oatmeal gruel.

The ability of fermenting oatmeal gruel was judged by means of the ability to reduce pH below 4.0 and form CFU at a level of $>10^8$ CFU/g wet weight.

15 The ability of resisting freeze-drying in oatmeal gruel was another selection criterium. In this connection the CFU concentration was measured after freeze-drying.

The result of the test above with oatmeal gruel is shown in table 2 below.

20

Table 2

Fermentation of oatmeal gruel with selected strains of Lactobacillus

	Strain 299	271	294	108
25				
	3.6	3.8	3.4	3.8
	8.0	6.5	8.1	6.5
	0.18	0.40	0.32	0.25
30	0.390	0.031	0.24	0.19
	0.57	0.43	0.55	0.44
	69	7	43	44
	0.0084	0.013	0.13	0.0026
35	65	86	94	98
	2×10^9	4×10^9	8×10^8	1×10^9

In addition the flavour of the selected 4 strains was evaluated in comparison with on one hand a commercial

yoghurt culture (*Streptococcus thermophilus* and *Lactobacillus bulgaricus*) and on the other hand a commercial culture of acidophilus sourmilk (*Lactobacillus acidophilus*) using the same evaluation symbols as above. The results are given in Table 3 below.

Table 3

Flavour of oatmeal gruel fermented with strains of *Lactobacillus*

10	Yoghourt	Acidophilus	299	271	294	108
		sourmilk				
15	3	2	5	4	3	1

On the basis of these values the strains 299 and 271 were judged to be of special interest and are described in further detail below.

Description of *Lactobacillus* strains 299 and 271

The strains 299 and 271, which were both isolated from healthy human intestinal mucosa, have been deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH on July 2, 1991 and have been given the deposition numbers DSM 6595 (299) and DSM 6594 (271).

Phenotype description

The strains 299 and 271 are Gram positive, catalase negative rods growing on Rogosa agar at pH 5.5. The capacity of the strains to ferment different carbohydrates is shown in Table 4. The tests have been carried out by means of the API 50 CH in accordance with the instructions of the manufacturer.

Table 4Ability to form acid from different carbohydrates

5		Strains	
		299	271
	1. Glycerol	-	-
	2. Erythrithol	-	-
10	3. D-arabinose	-	-
	4. L-arabinose	+	-
	5. Ribose	+	+
	6. D-xylose	-	-
	7. L-xylose	-	-
15	8. Adonithol	-	-
	9. β -methyl-xyloside	-	-
	10. Galactose	+	+
	11. D-glucose	+	+
	12. D-fructose	+	+
20	13. D-mannose	+	+
	14. L-sorbose	-	+
	15. Rhamnos	-	+
	16. Dulcitol	-	-
	17. Inositol	-	+
25	18. Mannitol	+	+
	19. Sorbitol	+	+
	20. α -methyl-D-mannoside	+	+
	21. α -methyl-D-glucoside	-	+
	22. N-acetyl-glucosamine	+	+
30	23. Amygdalin	+	+
	24. Arbutin	+	+
	25. Esculin	+	+
	26. Salicin	+	+
	27. Cellobiose	+	+
35	28. Maltose	+	+
	29. Lactose	+	+
	30. Melibiose	+	-
	31. Saccharose	+	+
	32. Trehalose	+	+
40	33. Inulin	-	-
	34. Melezitose	+	+
	35. D-raffinose	-	-
	36. Amidon	-	-
	37. Glycogene	-	-
45	38. Zylitol	-	-
	39. β -gentiobiose	+	+
	40. D-turanose	+	+
	41. D-lyxose	-	+
	42. D-tagatose	-	+
50	43. D-fucose	-	-
	44. L-fucose	-	-
	45. D-arabitol	-	-
	46. L-arabitol	-	-
	47. Gluconate	+	+
55	48. 2-keto-gluconate	-	-
	49. 5-keto-gluconate	-	-

Phenotypically strain 299 can be identified as *Lactobacillus plantarum* (only raffinose deviated from the test pattern for *L. plantarum* ATCC 14917^T; this is the type strain for the species *L. plantarum*, that is the strain which defines the species). 271 can be identified as *Lactobacillus casei* subsp. *rhamnosus* (corresponds completely to the type strain for the species).

10 Genotype description

The two strains have been examined as to the cleavage pattern of the chromosome DNA in connection with cleavage with *EcoRI*, through restriction-endonuclease analysis - REA - (method according to Ståhl M, Molin G, Persson A, Ahrné S & Ståhl S, *International Journal of Systematic Bacteriology*, 40:189-193, 1990). Schematically REA can be described as follows:

- (1) Chromosome DNA is isolated from the strains involved in the study;
- 20 (2) The DNA is cleaved with restriction enzymes;
- (3) The cleaved DNA fragments are separated as to size by agarose gel electrophoresis;
- (4) The band patterns of the different strains are registered and interpreted by means of a laser
- 25 densitometer and associated programs. The differences between the strains regarding the REA-pattern can be expressed mathematically by means of principal component analysis. 1990).

Furthermore an examination has been carried out referring to the contents of plasmids (method according to Ahrné S, Molin G & Ståhl S, *Systematic and Applied Microbiology* 11:320-325, 1989).

Strain 299: This strain contains four plasmids which are of the sizes of 4 MDal, 9 MDal, 20 MDal and 35 MDal, respectively. The cleavage pattern of the chromosomal DNA is shown in Figure 1. The lane marked with 299 shows the pattern of strain 299 and the lanes marked with a v represent a genetical variant of strain 299 from two different isolates; this variant was one of the 20 strains that were tested on humans

and has in Table 1 been denoted as A1; lane s denotes the standard, High M_r DNA Markers (AEH; BRL, Bethesda Research Laboratories, Life Technologies, Inc.). The variant of 299 can by means of common phenotype tests not be separated from
5 299. Also genetically 299 and 299v are very close. The variant has also proved to have the same ability to be established in human intestinal mucosa.

Strain 271: This strain contains two plasmids with a size of 3 MDal and 5 MDal, respectively. The cleavage pattern of
10 the chromosomal DNA of the strain is shown in Figure 2, as lane A; lane v shows a genetical variant of strain 271; and lane s denotes the same standard as in Figure 1. The variant of 271 can with common phenotype tests not be separated from 271. Also genetically 271 and 271v are very close. The
15 variant also has turned out to have the same ability to colonize the human intestinal mucosa as the sister strain.

Genetically the two examined strains differ essentially. They also differ significantly from the respective type strain.

20

Cultivation of Lactobacillus 299


- An inoculate from a freezer of -80°C is added to 50 ml Lactobacillus Carrying Medium (LCM, Eftthymion & Hansen, J. Infect. Dis., 110:258-267, 1962) or Rogosa,
- 25 - is incubated for about 40 hours at 37°C ,
- 50 ml is inoculated into 500 ml LCM,
- is incubated about 40 hours at 37°C ,
- 500 ml is inoculated into 5 litres,
- is incubated about 25-30 hours at 37°C ,
- 30 - is centrifuged at 10 000 rpm for 10 minutes,
- is washed once in a physiological salt solution,
- the pellet is dissolved in about 1 litre of physiological salt solution.


This amount is estimated to be sufficient for about
35 400-500 l of oatmeal gruel. Cultivation media are not optimized. Rogosa worked better than LCM, possibly due to a better buffer function. 2% glucose was added to LCM. The same procedure can be used for producing the other Lactobacillus strains.

Biological test on rat

Rats having a weight of 250-300 g were subjected to a standard operation to develop an abscess in the abdominal cavity by isolating and puncturing a part of the large intestine by which a constant leakage of intestinal contents out into the abdominal cavity was obtained which caused an abscess within 24 hours, sepsis and subsequent high rate of mortality. Three groups of 30 animals each were used. Group 1 was an untreated control group, Group 2 was treated with antibiotics, by injection, and Group 3 was supplied with lactobacilli in the form of a fermented oatmeal gruel to the stomach. The Lactobacillus strain which was used had been isolated from rat intestinal mucosa and in tests proved to be able to colonize and become established in rat intestines.

Evaluation of the test was made by analysis of the content of bacteria in the blood, something which is equivalent to sepsis, as well as cultures from the abdominal cavity and intestines. The result shows that all animals in Group 1 had bacteria in the blood, which should lead to a very high rate of mortality. In Groups 2 and 3 similar results were obtained with the occurrence of bacteria in 3 of 30 animals, however, to a much lesser extent than in Group 1.

MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on page <u>4</u> , line <u>37</u> of the description ¹	
A. IDENTIFICATION OF DEPOSIT ¹	
Further deposits are identified on an additional sheet <input type="checkbox"/> ²	
Name of depositary institution ⁴ DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH	
Address of depositary institution (including postal code and country) ⁴ Mascheroder Weg 1B D-3300 BRAUNSCHWEIG Deutschland	
Date of deposit ³ 1991-07-02	Accession Number ⁴ DSM 6594
B. ADDITIONAL INDICATIONS ¹ (leave blank if not applicable). This information is continued on a separate attached sheet <input type="checkbox"/>	
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE ¹ (if the indications are not for all designated States)	
D. SEPARATE FURNISHING OF INDICATIONS ¹ (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later ¹ (Specify the general nature of the indications e.g., "Accession Number of Deposit")	
E. <input checked="" type="checkbox"/> This sheet was received with the international application when filed (to be checked by the receiving Office)	
 _____ (Authorized Officer)	
<input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau ¹⁰	
_____ (Authorized Officer)	

MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on page <u>4</u> , line <u>36</u> of the description ¹	
A. IDENTIFICATION OF DEPOSIT ¹	
Further deposits are identified on an additional sheet <input type="checkbox"/> ²	
Name of depositary institution ³	
DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH	
Address of depositary institution (including postal code and country) ⁴	
Mascheroder Weg 1B D-3300 BRAUNSCHWEIG Deutschland	
Date of deposit ⁵	Accession Number ⁶
1991-07-02	DSM 6595
B. ADDITIONAL INDICATIONS ⁷ (leave blank if not applicable). This information is continued on a separate attached sheet <input type="checkbox"/>	
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE ⁸ (if the indications are not for all designated States)	
D. SEPARATE FURNISHING OF INDICATIONS ⁹ (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later ¹⁰ (Specify the general nature of the indications e.g., "Accession Number of Deposit")	
E. <input checked="" type="checkbox"/> This sheet was received with the international application when filed (to be checked by the receiving Office)	
 (Authorized Officer)	
<input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau ¹¹	
was (Authorized Officer)	

CLAIMS

1. A process for isolation of a strain of *Lactobacillus*
5 having the ability to colonize and become established on
human intestinal mucosa in vivo, characterized in that lacto-
bacilli are isolated from human intestinal mucosa and pure
cultured in a suitable nutrient medium and then selected as
to the ability to colonize and become established in the
10 intestines.

2. A process according to claim 1, characterized in that
the ability to colonize and become established is tested by
means of oral administration and verification of the occur-
rence on the intestinal mucosa 10 days after the completion
15 of the administration.

3. A process according to claim 1 or 2, characterized in
that a selection also is made by a valuation of the bile
resistance, pH-resistance, ability of fermenting oatmeal and
producing flavour.

20 4. A *Lactobacillus* strain having the ability of coloniz-
ing human intestinal mucosa in vivo, characterized in being
obtained according to any of claims 1 - 3.

5. A *Lactobacillus* strain having the ability of coloniz-
ing human intestinal mucosa in vivo, characterized in being
25 *Lactobacillus plantarum* 299 DSM 6595,
Lactobacillus casei ssp. *rhamnosus* 271 DSM 6594,
or a variant thereof having an essentially corresponding REA-
pattern.

6. A composition for the prophylaxis or treatment of
30 infections in the gastro-intestinal tract, characterized in
comprising a strain of *Lactobacillus* having the ability to
colonize and become established on human intestinal mucosa in
vivo, which has been obtained according to any of the claims
1 - 3, in combination with a conventional carrier.

35 7. A composition according to claim 6, characterized in
comprising any of the strains
Lactobacillus plantarum 299 DSM 6595,
Lactobacillus casei ssp. *rhamnosus* 271 DSM 6594,
or a variant thereof having an essentially corresponding REA-

pattern.

8. A composition according to claim 6 or 7 for oral, enteral or rectal administration, characterized in being an oatmeal based nutrient solution fermented by the Lactobacillus strain.

9. Use of a nutrient composition fermented by a Lactobacillus strain according to claim 4 substituting antibiotics for the prophylaxis or treatment of bacterial infections in connection with surgical operations.

10. Use according to claim 9, characterized in that the strain is

Lactobacillus plantarum 299

DSM 6595,

Lactobacillus casei ssp. rhamnosus 271

DSM 6594,

- or a variant thereof having an essentially corresponding REA-pattern.

1/3





FIG. 1



FIG. 2

3/3

FIG. 3



INTERNATIONAL SEARCH REPORT

International Application No. PCT/SE 92/00528

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: A 61 K 35/74, C 12 N 1/20																	
II. FIELDS SEARCHED <div style="text-align: center; border: 1px solid black; padding: 2px;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; border: 1px solid black; padding: 2px;">Classification System</td> <td style="border: 1px solid black; padding: 2px;">Classification Symbols</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">IPC5</td> <td style="border: 1px solid black; padding: 5px;">A 61 K</td> </tr> </table> <div style="text-align: center; border: 1px solid black; padding: 2px;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in Fields Searched⁸</div> <p style="padding: 5px;">SE,DK,FI,NO classes as above</p>			Classification System	Classification Symbols	IPC5	A 61 K											
Classification System	Classification Symbols																
IPC5	A 61 K																
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 2px;">Category *</th> <th style="width: 60%; padding: 2px;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 30%; padding: 2px;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X,Y</td> <td style="padding: 5px;">EP, A2, 0271364 (BIOREM C.C.) 15 June 1988, see page 3, line 28 - line 32; page 3, line 57 - line 65; page 4, line 22 - line 24 claims ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-4,6</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">WO, A1, 9105850 (TARTUSKY GOSUDARSTVENNY UNIVERSITET) 2 May 1991, see the whole document ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-4,6</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">WO, A1, 9105851 (TARTUSKY GOSUDARSTVENNY UNIVERSITET) 2 May 1991, see the whole document ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-4,6</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">Dialog Information Services, File 155, Medline, accession no. 04639496, Medline accession no. 82182496, Bongetta R et al: "The colonization of Streptococcus faecium in human intestinal tract after oral administration", & Boll Ist Sieroter Milan Nov 1981, 60 (5) p381-5 ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-4,6</td> </tr> </tbody> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X,Y	EP, A2, 0271364 (BIOREM C.C.) 15 June 1988, see page 3, line 28 - line 32; page 3, line 57 - line 65; page 4, line 22 - line 24 claims ---	1-4,6	Y	WO, A1, 9105850 (TARTUSKY GOSUDARSTVENNY UNIVERSITET) 2 May 1991, see the whole document ---	1-4,6	Y	WO, A1, 9105851 (TARTUSKY GOSUDARSTVENNY UNIVERSITET) 2 May 1991, see the whole document ---	1-4,6	Y	Dialog Information Services, File 155, Medline, accession no. 04639496, Medline accession no. 82182496, Bongetta R et al: "The colonization of Streptococcus faecium in human intestinal tract after oral administration", & Boll Ist Sieroter Milan Nov 1981, 60 (5) p381-5 ---	1-4,6
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
X,Y	EP, A2, 0271364 (BIOREM C.C.) 15 June 1988, see page 3, line 28 - line 32; page 3, line 57 - line 65; page 4, line 22 - line 24 claims ---	1-4,6															
Y	WO, A1, 9105850 (TARTUSKY GOSUDARSTVENNY UNIVERSITET) 2 May 1991, see the whole document ---	1-4,6															
Y	WO, A1, 9105851 (TARTUSKY GOSUDARSTVENNY UNIVERSITET) 2 May 1991, see the whole document ---	1-4,6															
Y	Dialog Information Services, File 155, Medline, accession no. 04639496, Medline accession no. 82182496, Bongetta R et al: "The colonization of Streptococcus faecium in human intestinal tract after oral administration", & Boll Ist Sieroter Milan Nov 1981, 60 (5) p381-5 ---	1-4,6															
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top; padding: 2px;"> [*] Special categories of cited documents: ¹⁰ ^{"A"} document defining the general state of the art which is not considered to be of particular relevance ^{"E"} earlier document but published on or after the international filing date ^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) ^{"O"} document referring to an oral disclosure, use, exhibition or other means ^{"P"} document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top; padding: 2px;"> ^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention ^{"X"} document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step ^{"Y"} document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. ^{"Z"} document member of the same patent family </td> </tr> </table>			[*] Special categories of cited documents: ¹⁰ ^{"A"} document defining the general state of the art which is not considered to be of particular relevance ^{"E"} earlier document but published on or after the international filing date ^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) ^{"O"} document referring to an oral disclosure, use, exhibition or other means ^{"P"} document published prior to the international filing date but later than the priority date claimed	^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention ^{"X"} document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step ^{"Y"} document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. ^{"Z"} document member of the same patent family													
[*] Special categories of cited documents: ¹⁰ ^{"A"} document defining the general state of the art which is not considered to be of particular relevance ^{"E"} earlier document but published on or after the international filing date ^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) ^{"O"} document referring to an oral disclosure, use, exhibition or other means ^{"P"} document published prior to the international filing date but later than the priority date claimed	^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention ^{"X"} document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step ^{"Y"} document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. ^{"Z"} document member of the same patent family																
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search 3rd November 1992 </td> <td style="width: 50%; border: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report 05 - 11 - 1992 </td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;"> International Searching Authority <div style="text-align: center;">SWEDISH PATENT OFFICE</div> </td> <td style="border: 1px solid black; padding: 5px;"> Signature of Authorized Officer Mikael G:son Bergstrand </td> </tr> </table>			Date of the Actual Completion of the International Search 3rd November 1992	Date of Mailing of this International Search Report 05 - 11 - 1992	International Searching Authority <div style="text-align: center;">SWEDISH PATENT OFFICE</div>	Signature of Authorized Officer Mikael G:son Bergstrand											
Date of the Actual Completion of the International Search 3rd November 1992	Date of Mailing of this International Search Report 05 - 11 - 1992																
International Searching Authority <div style="text-align: center;">SWEDISH PATENT OFFICE</div>	Signature of Authorized Officer Mikael G:son Bergstrand																

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Dialog Information Services, File 155, Medline, Dialog accession no. 05441493, Medline accession no. 85057493, Justesen, T et al: "Normal cultivable microflora in upper jejunal fluid in children without gastrointestinal disorders", & J Pediatr Gastroenterol Nutr Nov 1984, 3 (5) p683-6 ---	1
Y	Dialog Information Services, File 155, Medline, Dialog accession no. 05420589, Medline accession no. 85036589, Brilis VI et al: "Adhesive properties of lactobacilli isolated from the human gastrointestinal tract", & Nahrung 1984, 28 (6-7) p635-40 ---	1
Y	Dialog Information Services, File 155, Medline, Dialog accession no. 05272203, Medline accession no. 84196203, Justesen T et al: "The normal cultivable microflora in upper jejunal fluid in healthy adults", & Scand J Gastroenterol Mar 1984, 19 (2) p279-82 -----	1

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 9 and 10, because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1 (iv): Methods for treatment of the human or animal body by surgery or therapy.

2. ☐ Claim numbers..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers..... because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This international Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the the claims. It is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.PCT/SE 92/00528

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on 30/09/92
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0271364	88-06-15	AU-B- 624067 AU-D- 8240687	92-06-04 88-06-16
WO-A1- 9105850	91-05-02	FR-A- 2656798	91-07-12
WO-A1- 9105851	91-05-02	NONE	